about
SCT in Jehovah's Witnesses: the bloodless transplantOral cyclic melphalan and dexamethasone for patients with AL amyloidosis.Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center.Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitisOutcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patientsMHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cellsMelphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trialA forgotten cause of kidney injury in chronic myelomonocytic leukemia.Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review.Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.Eradication of Helicobacter pylori: the results of a pilot study of 3, 5 & 7 day triple antibiotic regime with bismuth for one month.High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.Successful long-term management of aneurysm-associated chronic disseminated intravascular coagulation with low molecular weight heparin.Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation.Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis.Reassessing bronchial artery embolotherapy with newer spherical embolic materials.Case-based prediction of survival in colorectal cancer patients.Macroglossia – not always AL amyloidosisGynandroblastoma of ovary with juvenile granulosa cell component and heterologous intestinal type glandsExtranodal marginal zone lymphoma of mucosa-associated lymphoid tissue with amyloid deposition: a clinicopathologic case seriesHigh-dose melphalan and stem cell transplantation in AL amyloidosis with elevated cardiac biomarkersHeparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantationHigh-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillatorsSystemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripesSARS-CoV-2 Infection Associated Hemophagocytic Lymphohistiocytosis: An autopsy series with clinical and laboratory correlation.Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen
P50
Q28267204-0D160EF4-9212-4E37-96A2-2E73AA0CFA7FQ33771326-8856ED65-85F6-4AF8-B19A-73EDEB62B5E9Q34036226-77A184C8-75B3-48B4-81A3-B817CBABA579Q35184746-14CDBA44-7A81-44FE-A70C-8771AEDCE52EQ35485742-5DC26C60-BCBD-40E6-9842-854CFA8A8811Q35573814-99DD7292-3399-4A6F-BDC5-891AC22A3B6DQ36805878-D3BC138D-DE00-46BA-B12A-A97EE11EE5BDQ37299461-A62875B4-52EB-41DD-8353-3E189EC17C27Q38017208-82FD78F8-1E2B-4AAB-B968-3D7198C9C3C3Q42907761-5FE1A43A-266E-420E-972C-D46E8818EFC7Q44612312-FAB6104A-63E7-41B4-B921-4716AACD7C85Q46334504-708A2F89-C391-4F22-8299-4C0056A70064Q47271193-D8DC70D3-2B65-4A95-9680-A762B98A6B4FQ48123471-79328279-A6F2-425B-A047-3D5838B41CE5Q48143474-A6B2F5BA-F843-463F-986A-22CE736B7A0BQ48173755-DEC99CE6-F019-4890-9CE1-098C1AE8ADD1Q48362218-6ED8DA8F-30F9-4E37-8A52-DDC0E715618DQ51700460-DF715BF6-DF4F-42AA-8289-8B3D37331797Q52137581-02A484D7-61FC-448E-992E-89124C23BC34Q58294866-15D0B4A8-ACA7-4B10-A2F4-E210C06D3526Q71711718-FCFB54C5-AB00-4739-9D97-30E4C2EC7EA5Q83016888-4C763C47-BC3C-4E67-877E-96B8233B19E6Q89047530-CD17F23A-918B-4095-81B1-5BC282210E1EQ89107939-3E4FFBF3-8B88-444A-A3BE-180A81B3CA85Q91142731-5EA47AB1-D392-4E17-AC49-EBB4142D3BFAQ91313626-2EBAC82D-6117-4301-A22F-9DF765A8D74CQ95608275-AB7A0190-B09D-405F-80B8-8F178DDBEE02Q96581569-0FABCF7A-AA8B-4F22-9BA3-F91AE920B4AC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
John Sloan
@ast
John Sloan
@en
John Sloan
@es
John Sloan
@nl
John Sloan
@sl
type
label
John Sloan
@ast
John Sloan
@en
John Sloan
@es
John Sloan
@nl
John Sloan
@sl
prefLabel
John Sloan
@ast
John Sloan
@en
John Sloan
@es
John Sloan
@nl
John Sloan
@sl
P106
P21
P31
P496
0000-0001-7069-4528